FDA Grants Breakthrough Therapy Designation to Seres’ SER-155
Seres Therapeutics announced that the FDA granted Breakthrough Therapy designation to SER-155, their lead investigational drug, for reducing bloodstream infections in adults undergoing stem cell transplants. This designation is based on positive Phase 1b clinical trial data showing a significant reduction in infections compared to a placebo. A meeting with the FDA to discuss the […]